LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts

Journal of Thoracic Oncology

Volumn 11, Issue 4, 2016, Pages S152-

  Ramalingam, S ^a   Yang, J C H ^b   Lee, C K ^c   Kurata, T ^d   Kim, D W ^e   John, T ^f   Nogami, N ^g   Ohe, Y ^h   Janne P A ⁱ  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c ST GEORGE HOSPITAL   (Australia)

^d KANSAI MEDICAL UNIVERSITY HOSPITAL   (Japan)

^e Seoul National University Hospital   (South Korea)

^f OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^g NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^h NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; OSIMERTINIB;

ADVANCED CANCER; ADVERSE EVENT; ADVERSE OUTCOME; ARTICLE; ASIAN; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; EGFR GENE; EXON; FEMALE; FOLLOW UP; GENE DELETION; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARONYCHIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; STOMATITIS; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84995428398     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/S1556-0864(16)30324-0     Document Type: Article

References (0)